GCM
BTAI icon

Ghisallo Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Ghisallo Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,250
Closed -$607K – 461
2021
Q3 		$607K Sell
1,250
-12,813
-91% -$5.63M 0.02% 395
2021
Q2 		$6.54M Buy
+14,063
New +$7.67M 0.25% 103

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ghisallo Capital Management's BTAI Position: Q4 2021 in Review

Ghisallo Capital Management sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 1,250 shares — an estimated $607K sold.

Ghisallo Capital Management first reported a position in BTAI in Q2 2021 and held it in 2 quarters. The position peaked at $6.54M in Q2 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Ghisallo Capital Management reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 1,250 BioXcel Therapeutics shares in Q4 2021, an estimated $607K.
  • Ghisallo Capital Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's BioXcel Therapeutics position peaked at $6.54M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.